Xbrane Biopharma AB (publ) (7XB)

Overview

Xbrane Biopharma AB (publ) is a pioneering biotechnology company based in Solna, Sweden, established in 2008. The company is dedicated to the development, manufacture, and commercialization of biosimilars, which are biologic medical products highly similar to already approved biological medicines. Xbrane's core focus lies in providing accessible and cost-effective therapeutic solutions for various diseases, primarily targeting significant areas such as ocular diseases, cancer, rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis. Through its robust R&D efforts and advanced technological platforms, Xbrane aims to address the growing needs of patients globally by offering biosimilars that match the original products in quality, efficacy, and safety.

Products and Services

• Ximluci

Ximluci is a biosimilar to ranibizumab, developed for the treatment of various eye conditions including wet age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to choroidal neovascularization in adults. By offering an alternative to the original biologic, Xbrane aims to make these crucial treatments more accessible and affordable for patients worldwide.

• BIIB801

In the pre-clinical phase, BIIB801 emerges as a promising biosimilar candidate targeting diseases like rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis. Reflecting Xbrane's commitment to expanding its biosimilar portfolio, BIIB801 represents a step forward in providing broader treatment options for autoimmune disorders and inflammatory conditions.

• Xdivane

Xdivane is under development for the treatment of various cancers, including skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer. By focusing on these critical areas, Xdivane showcases Xbrane's efforts in contributing to the oncology field, where there is a significant demand for more affordable biologic therapies.

• Xtrudane

Focused on malignant diseases such as brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer, Xtrudane is another significant addition to Xbrane's oncology pipeline. The development of such biosimilars indicates the company's dedication to providing alternatives that could potentially lower treatment costs and increase patient access to lifesaving medications.

• Xdarzane

Targeting multiple myeloma, Xdarzane is part of Xbrane's ambitious project to introduce biosimilars for the treatment of various forms of cancer. Xdarzane embodies the company's strategic direction towards addressing the needs of patients suffering from complex hematologic conditions, aiming to offer them hope through more affordable and accessible treatment options.